New_variants : Spike

Total row(s): 53
Select item(s)
Key Findings
Original Article
(hover to see details)
Three significant mutations (L452R, W152C and S13I) were identified in the spike protein of the California variant B.1.427/B.1.429 with no particular difference from non-variant lineages (B.1.427, B.1.429, other Clade 20C lineages). 33991487
(Cell)
PMID
33991487
Date of Publishing: 2021 Jun 24
Title Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Author(s) nameDeng X, Garcia-Knight MA et al.
Journal Cell
Impact factor
27.35
Citation count: 6
Date of Entry 2021 Sep 13
Pseudovirus with L452R mutation showed higher infectivity in 293T cells (6.7- to 22.5-fold increase) and HAO cell line (5.8- to 14.7-fold increase) than D614G-Pseudovirus but slightly lower infectivity than N501Y-Pseudovirus. 33991487
(Cell)
PMID
33991487
Date of Publishing: 2021 Jun 24
Title Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Author(s) nameDeng X, Garcia-Knight MA et al.
Journal Cell
Impact factor
27.35
Citation count: 6
Date of Entry 18_28_28 Jul
Convalescent patients showed a 4-6.7-fold decrease whereas vaccinated recipients showed a 2-fold decrase in the neutralizing antibody titre to the Epsilon variant, indicating a moderate resistance to the antibodies produced by the individuals. 33991487
(Cell)
PMID
33991487
Date of Publishing: 2021 Jun 24
Title Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Author(s) nameDeng X, Garcia-Knight MA et al.
Journal Cell
Impact factor
27.35
Citation count: 6
Date of Entry 18_36_32 Jul
SARS-CoV-2 Epsilon variant (B.1.427/B.1.429) found in California showed a 20% higher transmissibility and higher viral RNA loads being detected in patients compared to non-variants. 33991487
(Cell)
PMID
33991487
Date of Publishing: 2021 Jun 24
Title Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Author(s) nameDeng X, Garcia-Knight MA et al.
Journal Cell
Impact factor
27.35
Citation count: 6
Date of Entry 18_28_50 Jul
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). Three pseudotypes encoding RFA346-8KFP, S459G, and ST477-8GK were not neutralised by the mAbs panel. Nine pseudotypes virus showed neutralisation for at least one mAb. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
The Alpha variant B.1.1.7 pseudotype was evaluated for neutralization sensitivity to serum samples obtained from mild/asymptomatic healthcare workers and severely SARS-CoV2 affected hospitalized cohorts. The fold decrease in potency was greater for the hospitalized samples than the mild illness cohorts. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
The neutralising potency of a panel of monoclonal antibodies (mAbs) were assessed against the SARS-CoV-2 Alpha variant (B.1.1.7) pseudovirus. This variant lowered the potency of three mAbs- COVA2-17, COVA1-12 and COVA1-21. These mAbs belonged to distinct clusters and do not compete for binding to the same epitope. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). Pseudotype virus encoding the S494D showed absolutely no neutralization activity to both COVA2-29 (cluster I) and COVA1-12 (cluster VI) mAbs. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). Pseudotype virus with L452K showed no neutralization activity to the cluster I mAb COVA2-29. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). Pseudotype virus encoding the KVG444-6TST, a multiple substitution shows reduced neutralization potency (3.7-fold) for mAb COVA2-29, a cluster I RBD-specific antibody. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). Pseudotype virus encoding the K417V substitution mutation showed reduced neutralising potency to the cluster III RBD-specific mAb COVA2-07. No neutralization activity was observed with mAb COVA2-04. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). A complete loss of neutralising activity of the cluster III RBD-specific mAb COVA1-16 was observed with the pseudotyped virus with P384A substitution 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
The serum from 18 seropositive healthcare workers with mild or severe SARS-CoV-2 infection were assessed for neutralization potency against the 7 potential escape mutations on spike protein. All samples except one showed good neutralising potency to the spike mutations and were found to be less impacted over the spike mutations against the individual mAbs. 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Potential amino acid change which results in escape mutants in SARS-CoV were recreated by a mutation in the SARS-CoV-2 Spike. The 12 pseudotypes were screened against a panel of monoclonal antibodies (mAbs). Pseudotype virus expressing the LF455YL showed reduced neutralization activity to a wide range of RBD-specific mAbs from different clusters- COVA2-29 (cluster I), COVA2-07 (cluster III) and COVA1-12 (cluster VI). 33713594
(Cell Rep)
PMID
33713594
Date of Publishing: 2021 Mar 23
Title The impact of Spike mutations on SARS-CoV-2 neutralization
Author(s) nameRees-Spear C, Muir L et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 10
Date of Entry 2021 Aug 6
Growth curves for GLA1 (N439/D614G) or GLA2 (N439K/D614G) virus isolates were assessed in Vero E6 cells with ACE2 and TMPRSS2 overexpression. No significant growth amongst the isolates were observed indicating that N439K mutation played no role in viral growth. 33621484
(Cell)
PMID
33621484
Date of Publishing: 2021 Jan 28
Title Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Author(s) nameThomson EC, Rosen LE et al.
Journal Cell
Impact factor
27.35
Citation count: 1
Date of Entry 2021 Aug 6
The most prevalent receptor binding motif (RBM) mutation N439K was subjected to phylogenetic analysis. N439K lineage i/B.1.141 was dominant in Scotland; while N439K lineage ii/B.1.258 were first sampled in Romania and currently spread to 32 other countries. The growth rate of N439K/D614G lineage(i) was similar compared to the N439/D614 or N439/D614G WT in Scotland. 33621484
(Cell)
PMID
33621484
Date of Publishing: 2021 Jan 28
Title Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Author(s) nameThomson EC, Rosen LE et al.
Journal Cell
Impact factor
27.35
Citation count: 1
Date of Entry 2021 Aug 6
Structure analysis of SARS-CoV-2 N439K Receptor Binding Domain (RBD) in complex with hACE2 at 2.8 resolution showed strong non-covalent salt bridges. These bridges enhanced the binding for hACE2 in the N439K variant, as similar to the SARS-CoV N439R variant. Double mutants of N439K/R and K417V mutations show that salt bridge loss at RBD position 417 is compensated by the one at position 439. This results in hACE2 affinity similar to the wild type. 33621484
(Cell)
PMID
33621484
Date of Publishing: 2021 Jan 28
Title Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Author(s) nameThomson EC, Rosen LE et al.
Journal Cell
Impact factor
27.35
Citation count: 1
Date of Entry 2021 Aug 6
The goal of this investigation was to see if COVID-19 convalescent people' CD8+ T-cell responses detect SARS-CoV-2 variants. Out of 45 mutations tested, only one matched a low-prevalence CD8+ epitope from the B.1.351 Spike. This means that nearly all anti-SARS-CoV-2 CD8+ T-cell responses should be able to recognise the newly identified variations. 33594378
(medRxiv)
PMID
33594378
Date of Publishing: 2021 Feb 12
Title New research: T cells of earlier Covid-19 patients recognise all 3 major new variants
Author(s) nameRedd AD, Nardin A et al.
Journal medRxiv
Impact factor
Cant find
Citation count: 1
Date of Entry 2021 Sep 13
Screening for H69/V70, associated with a S-gene target failure (SGTF) was used to detect VOC 202012/01 (lineage B.1.1.7). Other mutations co-occurring with H69/V70 including S: N501Y, S477N were also identified by whole-genome sequencing. 33478625
(Euro Surveill)
PMID
33478625
Date of Publishing: 2021 Jan
Title Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69V70, France, August to December 2020
Author(s) nameBal A, Destras G et al.
Journal Euro Surveill
Impact factor
7.37
Citation count: 1
Date of Entry 2021 Aug 6
Whole-genome sequencing for 2 S gene target failure (SGTF) samples showed that the S deletion 21765-21770 was present in 100% of the reads. It also leads to the removal of 2 amino acids (H69/V70) in the N-terminal domain of the S1 subunit of the S protein. 33478625
(Euro Surveill)
PMID
33478625
Date of Publishing: 2021 Jan
Title Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69V70, France, August to December 2020
Author(s) nameBal A, Destras G et al.
Journal Euro Surveill
Impact factor
7.37
Citation count: 1
Date of Entry 2021 Aug 6
The SARS-CoV-2 Alpha variant (501Y.V2), prevalent in early Sept and mid-Nov, and the Beta variant (501Y.V2), circulating since late Sept, was 10% and 75% more transmissible than the 501N lineage, respectively. 33413740
(Euro Surveill)
PMID
33413740
Date of Publishing: 2021 Jan
Title Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020
Author(s) nameLeung K, Shum MH et al.
Journal Euro Surveill
Impact factor
7.37
Citation count: 4
Date of Entry 18_28_50 Jul
The dynamic tracking of the SARS-CoV-2 shows that the D614G variant was predominant in Europe and North America but not in China. In the absence of positive selection pressure due to anti-viral drugs, human population genetics could be a possible reason for evolution of the virus. 33374416
(Genes (Basel))
PMID
33374416
Date of Publishing: 2020 Dec 24
Title Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation
Author(s) nameHuang SW, Miller SO et al.
Journal Genes (Basel)
Impact factor
3.759
Citation count: 1
Date of Entry 18_28_50 Jul
Population genetic analysis and phylodynamic analysis using global SARS-CoV-2 phylogenies suggests that 614G increases in frequency relative to 614D in a way that suggests a selective advantage. 33275900
(Cell)
PMID
33275900
Date of Publishing: 2020 Nov 19
Title Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Author(s) nameVolz E, Hill V et al.
Journal Cell
Impact factor
27.35
Citation count: 21
Date of Entry 18_37_51 Jul
A novel SARS-CoV-2 variant called the Y839 variant was reported in Portugal, which rapidly spread throughout the country by the end of April. This novel variant was imported from Italy and was more prevalent in the northern (22%) and central regions (59%) of Portugal. 33131453
(Emerg Microbes Infect)
PMID
33131453
Date of Publishing: 2020 Dec
Title Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal.
Author(s) nameBorges V, Isidro J et al.
Journal Emerg Microbes Infect
Impact factor
5.84
Citation count: 1
Date of Entry 18_28_50 Jul
Analysis of 12343 SARS-CoV-2 sequences from patients from 6 geographical locations led to the identification of 1234 mutations when compared to the reference sequence. ORF1ab 4715L and S protein 614G variants were postively correlated to fatality rates and number of infected cases. In BCG-vaccinated countries, the frequency of the S 614G variant was associated with higher fatality rate. 32699345
(J Hum Genet)
PMID
32699345
Date of Publishing: 2020 Dec
Title SARS-CoV-2 genomic variations associated with mortality rate of COVID-19
Author(s) nameToyoshima Y, Nemoto K et al.
Journal J Hum Genet
Impact factor
2.942
Citation count: 13
Date of Entry 18_29_59 Jul

Vaccine : Spike

Total row(s): 4
Select item(s)
Key Findings
Original Article
(hover to see details)
In a phase 1 trial, two types of RNA based vaccines were tested: a) BNT162b2, coding for membrane-bound full-length spike protein; b) BNT162b1 coding secreted domain which is trimerized. Milder systemic events were found with BNT162b2. Hence BNT162b2 was chosen for the next phase of trials. 33053279
(N Engl J Med)
PMID
33053279
Date of Publishing: 2020 Dec 17
Title Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
Author(s) nameWalsh EE, Frenck RW Jr et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 46
Date of Entry 2021 Jun 22
In a phase 1/2 trial, NVX-CoV2373, a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine was found to be safe and elicited an immune response that exceeded levels in COVID-19 convalescent serum. 32877576
(N Engl J Med)
PMID
32877576
Date of Publishing: 2020 Dec 10
Title Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Author(s) nameKeech C, Albert G et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 72
In a phase 1/2 trial, NVX-CoV2373, a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine was found to be safe and elicited an immune response that exceeded levels in COVID-19 convalescent serum. 32877576
(N Engl J Med)
PMID
32877576
Date of Publishing: 2020 Dec 10
Title Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Author(s) nameKeech C, Albert G et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 72
In a phase 1/2 trial, ChAdOx1 nCoV-19 vaccine induced both cellular and humoral immune responses. Spike-specific T cells responses were detectable by day 14 and spike-specifc IgG antibodies were detectable by day 28. Both responses were boosted after the second dose. Neutralising antibody responses were seen in all participants after the booster dose. 32702298
(Lancet)
PMID
32702298
Date of Publishing: 2020 Aug 15
Title Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Author(s) nameFolegatti PM, Ewer KJ et al.
Journal Lancet
Impact factor
43.38
Citation count: 162
Date of Entry 2021 Aug 3

Sequence : Spike

Total row(s): 51
Select item(s)
Key Findings
Original Article
(hover to see details)
Phylogenetic analysis of Israeli and Non-Israeli SARS-CoV-2 sequences revealed that the Israeli SARS-CoV-2 Strain containing P681H mutation originated from the B.1.1.50 Pangolin lineage. Pre-print (medRXiv)
Date of Publishing 2021 Mar 25
Title A unique SARS-CoV-2 spike protein P681H strain detected in Israel
Author(s) nameNeta S. Zuckerman, Shay Fleishon et al.
Date of Entry 2021 Jun 14
The study reports a newly identified SARS-CoV-2 Strain from Israel. The strain included a non-synonymous mutation in the S protein: P681H (C23604A) and additional four synonymous mutations, Nsp3:C7765T, Nsp12b: C13821T, Nsp16:T21111C, and C29545A. Pre-print (medRXiv)
Date of Publishing -
Title A unique SARS-CoV-2 spike protein P681H strain detected in Israel
Author(s) name -
Date of Entry 2021 Jun 14
Mutational and Co-mutational analysis of SARS-CoV-2 Sequences from India revealed different Co-mutation patterns and clade-specific mutations across seven Indian states and one union territory during term2 (April 2020 to July 2020) and term3 (August 2020 to December 2020). Pre-print (bioRXiv)
Date of Publishing 2021 Mar 25
Title Genomic surveillance and phylodynamic analyses reveal emergence of novel mutation and co-mutation patterns within SARS-CoV2 variants prevalent in India
Author(s) nameNupur Biswas, Priyanka Mallick et al.
Date of Entry 2021 Jun 14
Indian metadata was analyzed to associate the frequent mutations and co-mutation patterns with COVID-19 patient status (deceased, symptomatic, mild, and asymptomatic groups). Pre-print (bioRXiv)
Date of Publishing 2021 Mar 25
Title Genomic surveillance and phylodynamic analyses reveal emergence of novel mutation and co-mutation patterns within SARS-CoV2 variants prevalent in India
Author(s) nameNupur Biswas, Priyanka Mallick et al.
Date of Entry 2021 Jun 14
Both the clusters (C1, C2) identified in the Amazon basin showed 4 mutations in the ORF1ab region and 1 mutation in the Spike gene but at different positions within the region for each cluster. 33857136
(PLoS Negl Trop Dis)
PMID
33857136
Date of Publishing: 2021 Apr
Title Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin
Author(s) nameBallesteros N, Muñoz M et al.
Journal PLoS Negl Trop Dis
Impact factor
4.4
Citation count: 1
Mutation analysis of 469 complete Indian SARS-CoV-2 nucleotide sequences from GenBank revealed that five proteins ORF1ab, ORF3a, S, N, and M had multiple mutations in different variants. While six proteins ORF6, ORF7a, ORF7b, ORF8, ORF10, and E had a single mutation in each variant. 33623833
(Gene Rep)
PMID
33623833
Date of Publishing: 2021 Feb 19
Title Characterizing genomic variants and mutations in SARS-CoV-2 proteins from Indian isolates
Author(s) nameDas JK, Sengupta A et al.
Journal Gene Rep
Impact factor
0.61
Citation count: 1
Mutation analysis of 59MDW SARS-CoV-2 genomes (n=37, collected from JBSA/Lackland military members and beneficiaries from May 14, 2020, to July 28, 2020) revealed 109 nucleotide changes in the coding region of the SARS-CoV-2 genome (which caused 63 unique, non-synonymous amino acid mutations), one mutation in the 5-UTR, and two mutations in the 3UTR. 33609027
(Mil Med)
PMID
33609027
Date of Publishing: 2021 Feb 20
Title Whole-genome Sequencing of SARS-CoV-2: Using Phylogeny and Structural Modeling to Contextualize Local Viral Evolution
Author(s) name Nazario-Toole AE, Xia H, Gibbons TF.
Journal Mil Med
Impact factor
1.6
Citation count: 1
Mutation analysis of 59MDW SARS-CoV-2 genomes (n=37, collected from JBSA/Lackland military members and beneficiaries from May 14, 2020, to July 28, 2020) revealed 14 non-synonymous mutations in the structural proteins. The effect and the biochemical properties of all mutations were studied. 33609027
(Mil Med)
PMID
33609027
Date of Publishing: 2021 Feb 20
Title Whole-genome Sequencing of SARS-CoV-2: Using Phylogeny and Structural Modeling to Contextualize Local Viral Evolution
Author(s) name Nazario-Toole AE, Xia H, Gibbons TF.
Journal Mil Med
Impact factor
1.6
Citation count: 1
62 mutations identified, including 30 mis-sense mutations, in 22 Moroccan patient isolates showed that Spike_D614G and NSP12_P323L mutations were present in all the analyzed sequences, whereas N_G204R and N_R203K were present in 9 sequences. 33558859
(Biosaf Health)
PMID
33558859
Date of Publishing: 2021 Feb 3
Title Genetic diversity and genomic epidemiology of SARS-CoV-2 in Morocco
Author(s) nameBadaoui B, Sadki K et al.
Journal Biosaf Health
Impact factor
Cant find
Citation count: 1
Phylogenetic trees were also reconstructed based on the sequences of S genes 33542420
(Sci Rep)
PMID
33542420
Date of Publishing: 2021 Feb 4
Title Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans
Author(s) nameXue X, Shi J et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
Date of Entry 2021 Jul 28
Amino acid alignment of the S gene in SARS-CoV-2 and coronaviruses found in bat and pangolin. 33542420
(Sci Rep)
PMID
33542420
Date of Publishing: 2021 Feb 4
Title Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans
Author(s) nameXue X, Shi J et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
Date of Entry 2021 Jul 28
Phylogenetic analysis of SARS-CoV-2 strains' whole-genome from the various regions of the world. 33542420
(Sci Rep)
PMID
33542420
Date of Publishing: 2021 Feb 4
Title Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans
Author(s) nameXue X, Shi J et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
Date of Entry 2021 Jul 28
Phylogenetic analysis of deletion variants (red branches) and genetically diverse nondeletion variants revealed the origins of RDR variants and identified specific deletion clades/lineages. 33536258
(Science)
PMID
33536258
Date of Publishing: 2021 Feb 3
Title Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Author(s) nameMcCarthy KR, Rennick LJ et al.
Journal Science
Impact factor
20.57
Citation count: 6
SARS-CoV-2 immunosuppressed patients had recurrent deletions in the spike glycoprotein. The deletions altered immunodominant epitope positions within the NTD of S glycoprotein and caused resistance to a neutralizing antibody. 33536258
(Science)
PMID
33536258
Date of Publishing: 2021 Feb 3
Title Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Author(s) nameMcCarthy KR, Rennick LJ et al.
Journal Science
Impact factor
20.57
Citation count: 6
SARS-CoV-2 sequences from the GISAID Database (deposited from 1 December 2019 to 24 October 2020) were analyzed to identify and characterize the recurrent deletion regions in the SARS-CoV-2 spike protein. 33536258
(Science)
PMID
33536258
Date of Publishing: 2021 Feb 3
Title Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Author(s) nameMcCarthy KR, Rennick LJ et al.
Journal Science
Impact factor
20.57
Citation count: 6
SARS-CoV-2 sequences from the GISAID Database were analyzed to evaluate the geographic, genetic, and temporal abundance of recurrent deletion variants of S glycoprotein. 33536258
(Science)
PMID
33536258
Date of Publishing: 2021 Feb 3
Title Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Author(s) nameMcCarthy KR, Rennick LJ et al.
Journal Science
Impact factor
20.57
Citation count: 6
Complete Coding Sequence of surface glycoprotein (S) gene, reported from an immunocompromised cancer patient infected with long-term SARS-CoV-2 infection (Pittsburgh long-term infection 1). 33536258
(Science)
PMID
33536258
Date of Publishing: 2021 Feb 3
Title Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Author(s) nameMcCarthy KR, Rennick LJ et al.
Journal Science
Impact factor
20.57
Citation count: 6
Most frequent and prevalent mutation reported, with reference to Wuhan sequence (hCoV-19/Wuhan/WIV04/2019), was P323L in the non-structural protein 12 (94.7%) whereas the second frequent mutation was D614G in the Spike glycoprotein region (92.6%), followed by G71S in the non-structural protein 5 (70%). 33359061
(Int J Infect Dis)
PMID
33359061
Date of Publishing: 2020 Dec 21
Title Molecular epidemiology of COVID-19 in Oman: A molecular andsurveillance study for the early transmission of COVID-19 in thecountry
Author(s) nameAl-Mahruqi S, Al-Wahaibi A et al.
Journal Int J Infect Dis
Impact factor
3.42
Citation count: 1
The in vitro mutation analysis showed that the D614G mutation changes the spike protein sorting, enhances the trafficking of spike protein to the lysosome, and thus accelerates the entry of SARS-CoV-2 in uninfected cells. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
Phylogenetic analysis performed for the SARS-CoV-2 sequences taken from pharyngeal swabs of nine patients in Guangzhou, China indicated they were infected with the same viral strain since 100% identity was observed in Spike gene of SARS-CoV-2. 33235537
(Atmos Environ (1994))
PMID
33235537
Date of Publishing: 2020 Nov 20
Title Community evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission through air
Author(s) nameLin G, Zhang S et al.
Journal Atmos Environ (1994)
Impact factor
4.3
Citation count: 1
Mutation analysis of 212 SARS-CoV-2 sequences from Israel revealed 224 unique single nucleotide variants (141 non-synonymous variants, 72 synonymous variants, 11 variants in non-coding regions) and five genomic deletions at different locations. 33139704
(Nat Commun)
PMID
33139704
Date of Publishing: 2020 Nov 2
Title Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel
Author(s) nameMiller D, Martin MA et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 9
The in vitro and in vivo mutation analysis of Spike mutation D614G showed increased viral replication and viral infectivity in human cell lines (Calu-3), primary human airway tissue, and Syrian hamsters. 33106671
(Nature)
PMID
33106671
Date of Publishing: 2020 Oct 26
Title Spike mutation D614G alters SARS-CoV-2 fitness
Author(s) namePlante JA, Liu Y et al.
Journal Nature
Impact factor
24.36
Citation count: 38
Comparative variant analysis of genome sequences of eleven Lebanese SARS-CoV-2 isolates revealed forty unique missense variants. Of forty unique variants identified, eighteen were new mutations. 33091548
(Genomics)
PMID
33091548
Date of Publishing: 2020 Oct 20
Title Variant analysis of the first Lebanese SARS-CoV-2 isolates.
Author(s) nameAbou-Hamdan M, Hamze K et al.
Journal Genomics
Impact factor
3.9
Citation count: 1
Sequence alignment of residues in the 615 to 635 loop and the corresponding NTD binding pocket of representative CoV strains belonging to lineage B of Betacoronavirus. 33082295
(Science)
PMID
33082295
Date of Publishing: 2020 Nov 27
Title Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Author(s) nameBangaru S, Ozorowski G et al.
Journal Science
Impact factor
20.57
Citation count: 12
In-silico analysis of the SARS-CoV-2 protein sequences from 13 different countries revealed the predicted effect of mutations on protein stability. 32881907
(PLoS One)
PMID
32881907
Date of Publishing: 2020
Title Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight
Author(s) nameKhan MI, Khan ZA et al.
Journal PLoS One
Impact factor
2.87
Citation count: 7

Structure : Spike

Total row(s): 44
Select item(s)
Key Findings
Original Article
(hover to see details)
Structure of SARS-CoV-2 spike receptor binding domain (RBD) using computational methods predicts antibody RBD recognition signatures which can be used to design vaccine against Covid-19. Pre-print (bioRXiv)
Date of Publishing -
Title Structural and energetic profiling of SARS-CoV-2 antibody recognition and the impact of circulating variants
Author(s) name -
Date of Entry 2021 Jun 14
Binding of monoclonal antibody, B6-Fab to SARS-CoV/SARS-CoV-2 spike stem helix peptide, sterically interferes with the spike protein's fusion the membrane. B6 binds to the hydrophobic core of the stem helix bundle and disrupts its quaternary structure. It prevents S2 subunit refolding from the pre- to the post-fusion state and blocks viral entry. 33981021
(Nat Struct Mol Biol)
PMID
33981021
Date of Publishing: 2021 May 12
Title Structural basis for broad coronavirus neutralization
Author(s) nameSauer MM, Tortorici MA et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 5
Date of Entry 2021 Jul 28
SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain and Fab ab1 and VH ab8 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused refinement of RBD and VH ab8). Y501 shows increased ACE2 affinity and increased infectivity. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8. Y501 inserts into a cavity at the binding interface near Y41 of ACE2 and this interaction causes the increased ACE2 affinity of the N501Y mutant and its increased infectivity. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2). 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1). 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain. Y501 inserts into a cavity at the binding interface near Y41 of ACE2 and this interaction causes the increased ACE2 affinity of the N501Y mutant and its increased infectivity. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 . Y501 inserts into a cavity at the binding interface near Y41 of ACE2 and this interaction causes the increased ACE2 affinity of the N501Y mutant and its increased infectivity. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to human ACE2 ectodomain (focused refinement of RBD and ACE2). Y501 inserts into a cavity at the binding interface near Y41 of ACE2 and this interaction causes the increased ACE2 affinity of the N501Y mutant and its increased infectivity. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Structural characterization of the SARS-CoV-2 N501Y mutant spike protein ectodomain. Y501 inserts into a cavity at the binding interface near Y41 of ACE2 and this interaction causes the increased ACE2 affinity of the N501Y mutant and its increased infectivity. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
X-ray diffraction structure of SARS-CoV-2 Spike receptor binding domain binding to angiotensin-converting enzyme of Rhinolophus macrotis (bACE2-Rm), shows S-RBD binds to bACE2 with a KD = 2.78 μM and binds with a KD = 20.4 nM to hACE2. Y41H mutant reduces the binding capacity of bACE2 with spike RBD. 33335073
(Proc Natl Acad Sci U S A)
PMID
33335073
Date of Publishing: 2021 Jan 5
Title Cross-species recognition of SARS-CoV-2 to bat ACE2
Author(s) nameLiu K, Tan S et al.
Journal Proc Natl Acad Sci U S A
Impact factor
9.35
Citation count: 1
Monovalent hACE2 decoy CTC-445.2 binds to all the three RBDs of a single spike protein with a low nanomolar affinity and high specificity. The divalent CTC-445.2d shows about ~10 fold increase in the binding. 33154107
(Science)
PMID
33154107
Date of Publishing: 2020 Dec 4
Title De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
Author(s) nameLinsky TW, Vergara R et al.
Journal Science
Impact factor
20.57
Citation count: 7
Date of Entry 2021 Jul 28
Structural characterization of SARS-CoV-2 3Q-2P full-length prefusion spike trimer (C3 symmetry) of the leading subunit vaccine candidate (NVAX-CoV2373) from Novavax. 33082295
(Science)
PMID
33082295
Date of Publishing: 2020 Nov 27
Title Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Author(s) nameBangaru S, Ozorowski G et al.
Journal Science
Impact factor
20.57
Citation count: 12
Structural characterization of SARS-CoV-2 3Q-2P full-length dimers of spike trimers of the leading subunit vaccine candidate (NVAX-CoV2373) from Novavax. 33082295
(Science)
PMID
33082295
Date of Publishing: 2020 Nov 27
Title Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
Author(s) nameBangaru S, Ozorowski G et al.
Journal Science
Impact factor
20.57
Citation count: 12
Structure of SARS-CoV-2 Spike D614G variant without RBD. 32991842
(Cell)
PMID
32991842
Date of Publishing: 2020 Oct 29
Title Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Author(s) nameYurkovetskiy L, Wang X et al.
Journal Cell
Impact factor
27.35
Citation count: 52
Structural characterization of the complex of Spike protein with Ty1, which is an antibody fragment that binds to the receptor binding domain (RBD) of the viral protein, and neutralizes the virus. 32887876
(Nat Commun)
PMID
32887876
Date of Publishing: 2020 Sep 4
Title An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Author(s) nameHanke L, Vidakovics Perez L et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 20
Structural characterisation of SARS-CoV-2 Spike ectodomain 32755598
(Cell Rep)
PMID
32755598
Date of Publishing: 2020 Aug 11
Title A Carbohydrate-Binding Protein from the Edible Lablab Beans Effectively Blocks the Infections of Influenza Viruses and SARS-CoV-2
Author(s) nameLiu YM, Shahed-Al-Mahmud M et al.
Journal Cell Rep
Impact factor
7.7
Citation count: 7
Structure of SARS-CoV-2 rS2d (RBD to S2 double mutant ) down state spike protein trimer. 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Structural characterization of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q 2 Up RBD state)) construct . 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation.
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Structural characterization of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q all RBD down state)) construct. 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Structure of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q 1 Up RBD)) . 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Structural characterisation of SARS-CoV-2 spike glycoprotein bound to Fab 2-4 of mAb isolated from SARS-CoV-2 infected patients 32698192
(Nature)
PMID
32698192
Date of Publishing: 2020 Aug
Title Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Author(s) nameLiu L, Wang P et al.
Journal Nature
Impact factor
24.36
Citation count: 97
Cryo-EM structure of the SARS-CoV-2 S2 in the postfusion conformation. 32694201
(Science)
PMID
32694201
Date of Publishing: 2020 Sep 25
Title Distinct conformational states of SARS-CoV-2 spike protein
Author(s) nameCai Y, Zhang J et al.
Journal Science
Impact factor
20.57
Citation count: 66
Cryo-EM structure of the SARS-CoV-2 S protein in the prefusion conformation. 32694201
(Science)
PMID
32694201
Date of Publishing: 2020 Sep 25
Title Distinct conformational states of SARS-CoV-2 spike protein
Author(s) nameCai Y, Zhang J et al.
Journal Science
Impact factor
20.57
Citation count: 66

Drugs : Spike

Total row(s): 27
Select item(s)
Key Findings
Original Article
(hover to see details)
2466 drugs from DrugBank were used to computationally target against RBD of Spike protein in SARS-CoV-2 to obtain 18 favourable drugs with top docking scores, 6 of them formed stable complex by MD simulation, with 3 of them showing enhanced binding 34256255
(Comput Biol Med)
PMID
34256255
Date of Publishing: 2021 Aug
Title Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations
Author(s) name Kumar V, Liu H, Wu C.
Journal Comput Biol Med
Impact factor
2.93
Date of Entry 2021 Sep 5
Structural modelling and binding site analysis of human host cell transmembrane protease serine 2 (TMPRSS2), a protease involved in cleaving a spike protein domain of SARS-CoV-2 to facilitate membrane fusion, was done, followed by structure-based screening of drug-like compounds for it's inhibition. Compounds Otamixaban and NCGC00386945 were shown to exhibit potent activity against TMPRSS2 with an efficient activity in the viral entry assay whereas the compound UKI-1 showed promising activity against the serine protease but was inactive in the SARS-CoV-2 PP entry assay. 34136758
(ACS Pharmacol Transl Sci)
PMID
34136758
Date of Publishing: 2021 Jun 11
Title Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19
Author(s) nameHu X, Shrimp JH et al.
Journal ACS Pharmacol Transl Sci
Impact factor
14.357
Citation count: 1
Date of Entry 2021 Sep 5
This study was performed to explore the potential of different phytochemicals as candidate inhibitors of the HR1 domain in SARS-CoV-2 spike protein. Quantum computation-based den sity functional theory (DFT) analysis was constituted to analy ze the reactivity of these compounds with the receptor. 5 phyto chemicals, i.e., SilybinC, Isopomiferin, Lycopene, SilydianinB , and Silydianin are identified as novel and potent candidates for the inhibition of HR1 domain in SARS-CoV-2 spike protein. 34095308
(Biomed Res Int)
PMID
34095308
Date of Publishing: 2021
Title Virtual Screening of Phytochemicals by Targeting HR1 Domain of SARS-CoV-2 S Protein: Molecular Docking, Molecular Dynamics Simulations, and DFT Studies
Author(s) nameMajeed A, Hussain W et al.
Journal Biomed Res Int
Impact factor
2.14
Citation count: 1
Date of Entry 2021 Sep 5
In this study, phytochemicals (1,952 compounds) from eight potential medicinal plants used in Indian traditional medicine were meticulously collated, based on their usage in respirato ry disorders, along with immunomodulatory and anti-viral potential from contemporary literature. Further, these comp ounds were virtually screened against Receptor Binding Dom ain (RBD) of Spike protein. The potential hits in complex with spike protein were subjected to Molecular Dynamics simulati on (450 ns), to infer the stability of complex formation. Amo ng the compounds screened, Tellimagrandin-II from Syzygium aromaticum L. and O-Demethyl-demethoxy- curcumin from Curcuma longa L. were found to be highly potential due to their higher binding affinity and significant binding free energy (MM-PBSA), along with favorable ADMET properties and stable intermolecular interactions with hotspots. 34026798
()
PMID
34026798
Title Phytochemical Moieties From Indian Traditional Medicine for Targeting Dual Hotspots on SARS-CoV-2 Spike Protein : An Integrative in-silico Approach
Date of Entry 2021 Sep 5
Antiviral efficacy of Astemizole which inhibits the entry of SARS-CoV-2 Spike pseudoviruses into ACE2-expressed HEK293T cells by binding to the ACE2 receptor. 33932547
(Microb Pathog)
PMID
33932547
Date of Publishing: 2021 Apr 28
Title Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro
Author(s) nameWang X, Lu J et al.
Journal Microb Pathog
Impact factor
2.64
Citation count: 1
Date of Entry 2021 Aug 10
Cytotoxicity analysis of Astemizole which inhibits the entry of SARS-CoV-2 Spike pseudoviruses into ACE2-expressed HEK293T cells by binding to the ACE2 receptor. 33932547
(Microb Pathog)
PMID
33932547
Date of Publishing: 2021 Apr 28
Title Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro
Author(s) nameWang X, Lu J et al.
Journal Microb Pathog
Impact factor
2.64
Citation count: 1
Date of Entry 2021 Aug 10
Using computational tools to screen a library of marine seaweed compounds against the Spike protein RBD of the SARS-CoV-2 UK variant (VUI 202012/01). Dieckol cannot be used as a lead inhibitor against RBD. 33922914
(Mar Drugs)
PMID
33922914
Date of Publishing: 2021 Apr 25
Title Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study
Author(s) nameAatif M, Muteeb G et al.
Journal Mar Drugs
Citation count 1
Date of Entry 2021 Sep 5
Different potential repurposed drugs, including, chloroquine , hydroxychloroquine, ivermectin, remdesivir, and favipiravir, were screened in the present study. Molecular docking of these drugs with different SARS-CoV-2 target proteins, including spike and membrane proteins, RdRp, nucleoproteins, viral proteases, and nsp14, was performed. Molecular dynamics simulation and MM-PBSA calculation were also conducted. Ivermectin and remdesivir were found to be the most promising drugs. 33746908
()
PMID
33746908
Title Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
Date of Entry 2021 Sep 5
In this Study the work aims to find molecules that can inhibit the attraction between the Spike proteins of the SARS-COV-2 virus and human ACE2. The results of molecular docking positioned four molecules at the interaction site Tyr-491(Spike)-Glu-37(ACE2) and one at the site Gly-488(Spike)-Lys-353(ACE2). 33583954
(J Mol Struct)
PMID
33583954
Date of Publishing: 2021 May 15
Title Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface
Author(s) name Faria SHDM, Teleschi JG.
Journal J Mol Struct
Impact factor
2.19
Citation count: 1
Date of Entry 2021 Sep 5
Bisoxatin, a laxative compound can inhibit ACE2-Spike protein interactions 33184246
(J Biosci)
PMID
33184246
Date of Publishing: 2020
Title Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods
Author(s) nameUnni S, Aouti S et al.
Journal J Biosci
Impact factor
1.72
Citation count: 1
Date of Entry 2021 Jun 15
Computational screening of 19 different inhibitor molecules by Molecular docking,drug-like and ADMETprediction indicates HIV protease, anti-inflammatory and antibiotic inhibitors are potential lead drug molecules against spike protein and antimalarial drugs show less binding affinity against spike protein. 33152616
(J Mol Graph Model)
PMID
33152616
Date of Publishing: 2021 Jan
Title Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus
Author(s) namePrashantha CN, Gouthami K et al.
Journal J Mol Graph Model
Impact factor
1.93
Citation count: 1
Date of Entry 2021 Sep 5
Computational screening of more than 3800 FDA-approved drugs against RBD S1-ACE2 interface by flexible ligand docking, ADME property calculations, and protein-ligand interaction maps indicate silodosin a good inhibitor of spike protein. 33103586
(J Biomol Struct Dyn)
PMID
33103586
Date of Publishing: 2020 Oct 25
Title High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein
Author(s) nameAwad IE, Abu-Saleh AAA et al.
Journal J Biomol Struct Dyn
Impact factor
3.22
Citation count: 1
Date of Entry 2021 Sep 5
Virtual screening and in silico pharmacophore modelling of 764913 compounds to explore safe oral drugs against Receptor Binding Domain (RBD) of SARS-CoV-2,but only eight molecules fit the criteria for safe oral drugs. 33083627
(Heliyon)
PMID
33083627
Date of Publishing: 2020 Oct
Title Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment
Author(s) name Shehroz M, Zaheer T, Hussain T.
Journal Heliyon
Impact factor
1.65
Citation count: 1
Date of Entry 2021 Sep 5
Novel peptidomimetics were designed based on crucial interacting interface residues from ACE2-SARS-CoV-2 binary interactions, the top lead peptidomimetics were screened for further validation using computational method and in that 4 lead peptidomimetic compounds shows inhibition against spike protein in cell-based assays. 33072222
(Cell Mol Bioeng)
PMID
33072222
Date of Publishing: 2020 Oct 13
Title Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein
Author(s) name Alagumuthu M, Rajpoot S, Baig MS.
Journal Cell Mol Bioeng
Impact factor
2.36
Citation count: 1
Date of Entry 2021 Sep 5
The anti-protease activity of three polyphenolic compounds- mangiferin, glucogallin, and phlorizin, on SARS-CoV-2 main protease (Mpro) and TMPRSS2 protein were analysed and predicted by docking studies. Molecular docking studies and MD simulation showed that all three compounds may have the potential to be used as safe protease inhibitors thus helping prevent SARS-CoV-2 spike protein priming and viral protein post-translational modification. The absorption, distribution, metabolism, and excretion (ADME) studies showed that the three compounds showed less absorption from the GI tract, no Blood brain barrier permeability, and no effect on the CYP2D6, CYP3A4, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 cytochrome enzymes. They also showed no inhibitory effect on liver enzymes and thus no hepatotoxicity and no effect on the metabolism of other essential drugs. 33050360
(Molecules)
PMID
33050360
Date of Publishing: 2020 Oct 10
Title Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study
Author(s) nameSingh R, Gautam A et al.
Journal Molecules
Impact factor
3.01
Citation count: 2
Date of Entry 2021 Sep 5
Present study was aimed to target SARS-CoV-2 S-RBD with novel bioactive compounds to retrieve potential candidates that could serve as anti-coronavirus disease 2019 drugs. 33041407
(J Mol Liq)
PMID
33041407
Date of Publishing: 2020 Dec 15
Title Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach
Author(s) nameMuhseen ZT, Hameed AR et al.
Journal J Mol Liq
Impact factor
4.85
Citation count: 4
Date of Entry 2021 Sep 5
In silico screening of 4015 small molecules against ACE2 specific Receptor binding domain on S-protein in SARS-CoV-2 was carried out, followed by molecular docking and molecular dynamic simulation, which suggests that Glycyrrhizic acid (GA) may potentially inhibit target activity. 32765844
(F1000Res)
PMID
32765844
Date of Publishing: 2020
Title In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19
Author(s) nameBr B, Damle H et al.
Journal F1000Res
Impact factor
2.64
Citation count: 3
Date of Entry 2021 Sep 5
High throughput virtual screening approach was used to investigate FDA approved LOPAC library drugs against both the receptor binding domain of spike protein (S-RBD) and ACE2 host cell receptor. Evidently, GR 127935 hydrochloride hydrate, GNF-5, RS504393, TNP, and eptifibatide acetate were found binding to virus binding motifs of ACE2 receptor. Additionally, KT203, BMS195614, KT185, RS504393, and GSK1838705A were identified to bind at the receptor binding site on the viral S-protein.These identified molecules may effe ctively assist in controlling the rapid spread of SARS-CoV-2 by not only potentially inhibiting the virus at entry step but are also hypothesized to act as anti-inflammatory agents, which could impart relief in lung inflammation. 32754161
(Front Immunol)
PMID
32754161
Date of Publishing: 2020
Title Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach
Author(s) name Choudhary S, Malik YS, Tomar S.
Journal Front Immunol
Impact factor
4.53
Citation count: 14
Date of Entry 2021 Sep 5
Virtual screening of 11 potent antimalarial compounds derived from the core structure of Artemisinin and identification of 3 compounds namely Artesunate, Artemisinin, and Artenimol to show its efficacy and potency compared to HCQ for SARS-CoV-2 through molecular dynamics study. 32696720
(J Biomol Struct Dyn)
PMID
32696720
Date of Publishing: 2020 Jul 22
Title Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19
Author(s) name Sehailia M, Chemat S.
Journal J Biomol Struct Dyn
Impact factor
3.22
Citation count: 6
Date of Entry 2021 Aug 2
Stilbenoids(plant based) were repurposed and checked for biological activity against the SARS-CoV-2 spike protein and human ACE2 receptor complex. Four compounds with good affinity were found out of which Resveratol was shown to be most promising. 32345140
(J Biomol Struct Dyn)
PMID
32345140
Date of Publishing: 2020 May 12
Title Stilbene-based natural compounds as promising drug candidates against COVID-19
Author(s) name Wahedi HM, Ahmad S, Abbasi SW.
Journal J Biomol Struct Dyn
Impact factor
3.22
Citation count: 63
Date of Entry 2021 Sep 5
3 inhibitors originally developed for antiviral therapy against HIV, influenza A and B and respiratory infections were chosen and investigated for their potential effectiveness and interaction affinity towards the SARS-CoV-2 Spike protein 32295237
(Viruses)
PMID
32295237
Date of Publishing: 2020 Apr 14
Title Molecular Investigation of SARSCoV-2 Proteins and Their Interactions with Antiviral Drugs
Author(s) nameCalligari P, Bobone S et al.
Journal Viruses
Impact factor
3.76
Citation count: 34
Date of Entry 2021 Sep 5
This study reports the effective treatment of Tocilizumab (TCZ) therapy in COVID-19 infected patients. In most patients, elevated CRP levels and IL-6 levels gradually decreased after TCZ therapy. For critically ill patients, repeated doses (two to three doses) of TCZ improved the health conditions. 32253759
(J Med Virol)
PMID
32253759
Date of Publishing: 2020 Jul
Title Tocilizumab treatment in COVID19: A single center experience
Author(s) nameLuo P, Liu Y et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 351
Aim of this study was to discover the compounds that can bind to the RBD of spike protein in the prefusion conformation and to the site of the connective interface of spike-ACE2 complex protein, to prevent viral spike proteins to bind to the human ACE2 proteins in COVID-19 disease progression. Virtual screening gave 39 potential compounds from 2321 total compounds, out of which 2 showed most affinity. -
()
PMID
-
Title The discovery of potential natural products for targeting SARS-CoV-2 spike protein by virtual screening
Date of Entry 2021 Sep 5
In this study, we focused on the human host cell transmembrane protease serine 2 (TMPRSS2), which plays an important role in the viral life cycle by cleaving the spike protein to initiate membrane fusion. we developed an efficient pharmacophore- based approach and applied a large-scale in silico database screening for small molecule inhibitors against TMPRSS2. -
()
PMID
-
Title Discovery of TMPRSS2 inhibitors from virtual screening
Date of Entry 2021 Sep 5
Inhibitory potential of oleuropein and 3-hydroxytyrosol against structural Spike protein and non-structural proteins (PLpro, Mpro and RdRp) of SARS-CoV-2 was studied and oleuropein was found to be the best potential candidate against RdRP. -
()
PMID
-
Title In Silico Screening of the Phenolic Compound Oleuropein and Its Hydrolysis Product 3- Hydroxytyrosol Against Certain Structural and Non-Structural Proteins of SARS-CoV-2
Date of Entry 2021 Sep 5

Diagnostics : Spike

Total row(s): 4
Select item(s)
Key Findings
Original Article
(hover to see details)
This study reports a rapid and inexpensive diagnostic test, called RAPID 1.0 (Real-time Accurate Portable Impedimetric Detection prototype 1.0) which provides a result within 4 minutes. The RAPID technology is based on electrochemical impedance spectroscopy (EIS), which transforms the binding event between the SARS-CoV-2 spike protein and receptor protein ACE2 into a detected electrical signal. The signal can be read through a desktop instrument or a smartphone. 33997767
(Matter)
PMID
33997767
Date of Publishing: 2021 Jul 7
Title Low-cost Biosensor for Rapid Detection of SARS-CoV-2 at the Point-of-Care
Author(s) nameTorres MDT, de Araujo WR et al.
Journal Matter
Detection of SARS CoV-2 IgM, and IgA antibodies from Sera samples using Luminex bead-based assay by targeting SARS-CoV-2 spike and nucleocapsid antigens. The neutralizing and binding IgG, IgA, and IgM antibody levels were higher for severe than mild cases in the early convalescent phase (<6 weeks). 33227340
(J Virol Methods)
PMID
33227340
Date of Publishing: 2021 Feb
Title Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay
Author(s) nameMariën J, Ceulemans A et al.
Journal J Virol Methods
Impact factor
1.76
Citation count: 1
A total antibody test that detects IgG and IgM concentrations against the spike protein in a single cartridge with maximum specificity 32710669
(J Med Virol)
PMID
32710669
Date of Publishing: 2021 Feb
Title Validation and performance comparision of three SARS-CoV-2 antibody assays
Author(s) namePaiva KJ, Grisson RD et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 4
A lateral flow assay that detects IgG and IgM antibody concentration against spike protein in two different cartridges with just maximum specificity 32710669
(J Med Virol)
PMID
32710669
Date of Publishing: 2021 Feb
Title Validation and performance comparision of three SARS-CoV-2 antibody assays
Author(s) namePaiva KJ, Grisson RD et al.
Journal J Med Virol
Impact factor
2.07
Citation count: 4

Molecular_interactions : Spike

Total row(s): 38
Select item(s)
Key Findings
Original Article
(hover to see details)
Molecular interaction of B6 (monoclonal antibody) and spike protein of SARS-CoV-2. 33981021
(Nat Struct Mol Biol)
PMID
33981021
Date of Publishing: 2021 May 12
Title Structural basis for broad coronavirus neutralization
Author(s) nameSauer MM, Tortorici MA et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 5
Date of Entry 2021 Jul 28
Molecular docking of astemizole to ACE2 shows that it can bind to ACE2 and inhibit the invasion of SARS-CoV-2 spike pseudoviruses. 33932547
(Microb Pathog)
PMID
33932547
Date of Publishing: 2021 Apr 28
Title Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro
Author(s) nameWang X, Lu J et al.
Journal Microb Pathog
Impact factor
2.64
Citation count: 1
Date of Entry 2021 Aug 10
Based on the intermolecular contact maps (COCOMAPS tool) of ACE2-S complex structure, three short peptides (pep1c, pep1d, pep1e) were designed to block virus-host interaction in the early stages of SARS-CoV-2 infection. 33918595
(Molecules)
PMID
33918595
Date of Publishing: 2021 Apr 9
Title Native Structure-Based Peptides as Potential ProteinProtein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor
Author(s) nameOdolczyk N, Marzec E et al.
Journal Molecules
Impact factor
3.01
Citation count: 1
Date of Entry 2021 Aug 12
Complex of ACE2 receptor and N501Y spike protein ectodomains shows Y501 inserted into a cavity at the binding interface near Y41 of ACE2 providing a structural explanation for the increased ACE2 affinity of the N501Y mutant, and its increased infectivity, but the mutation does note cause large structural changes. 33914735
(PLoS Biol)
PMID
33914735
Date of Publishing: 2021 Apr 29
Title Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Author(s) nameZhu X, Mannar D et al.
Journal PLoS Biol
Impact factor
7.62
Citation count: 2
Comparative analysis of the docking scores obtained by molecular docking of SARS-CoV-2 S1 RBD domain to amyloid and heparin to heparin binding proteins. This shows S1-heparin has the highest docking score and as the temperature increases from 25° C to 40° C, the binding affinity for SARS-CoV-2 S1 protein complexes decreases. 33789211
(Biochem Biophys Res Commun)
PMID
33789211
Date of Publishing: 2021 May 21
Title SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration
Author(s) name Idrees D, Kumar V.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 1
Date of Entry 2021 Aug 12
Heparin binding accelerates the aggregation of pathological amyloid proteins in the brain. Comparative study to the docking score of SARS-CoV-2 S1-heparin complex to amyloid forming proteins shows molecular interaction of the SARS-COV-2 Spike S1 RBD and Heparin shows a high docking score of -282.57. 33789211
(Biochem Biophys Res Commun)
PMID
33789211
Date of Publishing: 2021 May 21
Title SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration
Author(s) name Idrees D, Kumar V.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 1
Date of Entry 2021 Aug 12
SARS-CoV-2 S1 RBD binds heparin binding proteins including A, -synuclein, tau, prion, and TDP-43 RRM. The heparin binding site of S1 protein assists the binding to amyloid proteins to the viral surface and initate aggregation of these proteins, leading to neurodegenration in brain. This provides a reasonable explanation for the neurodegenerative distresses caused by a COVID infection. 33789211
(Biochem Biophys Res Commun)
PMID
33789211
Date of Publishing: 2021 May 21
Title SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration
Author(s) name Idrees D, Kumar V.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 1
Date of Entry 2021 Aug 12
The study compares the similarities and differences in the structure of heparin sulfate (HS) in human and bat lungs. Also, discusses about the binding capacity of spike protein of SARS-CoV-2 with homosapiens and chiroptera's lung heparin sulfate. 33712145
(Carbohydr Polym)
PMID
33712145
Date of Publishing: 2021 May 15
Title Heparan sulfates from bat and human lung and their binding to the spike protein of SARS-CoV-2 virus
Author(s) nameYan L, Song Y et al.
Journal Carbohydr Polym
Impact factor
6.23
Citation count: 1
Date of Entry 2021 Aug 11
Molecular interaction study between polymorphic spike protein and human ACE2 33542420
(Sci Rep)
PMID
33542420
Date of Publishing: 2021 Feb 4
Title Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans
Author(s) nameXue X, Shi J et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
Date of Entry 2021 Jul 28
Surface plasmon resonance (SPR) was used to compare the kinetics of SARS-CoV-2 S protein both D614 and D614G binding to human ACE2. D614G decreases the affinity for ACE2 by increasing the rate of dissociation. 32991842
(Cell)
PMID
32991842
Date of Publishing: 2020 Oct 29
Title Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Author(s) nameYurkovetskiy L, Wang X et al.
Journal Cell
Impact factor
27.35
Citation count: 52
Date of Entry 2021 Jun 15
Structural characterization of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q 1 Up RBD)) construct. And determing its binding with the antibody CR3022 and human cell receptor ACE2. 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Structural characterization of SARS-CoV-2 spike glycoprotein (subdomain 1 to S2 quadruple mutant (u1S2q 2 Up RBD state)) construct and determing its binding with the antibody CR3022 human cell receptor ACE2 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Structural characterization of SARS-CoV-2 spike glycoprotein (RBD to S2 double mutant (rS2d)) constructs. And determing its binding with the antibody CR3022 and human cell receptor ACE2. 32699321
(Nat Struct Mol Biol)
PMID
32699321
Date of Publishing: 2020 Oct
Title Controlling the SARS-CoV-2 spike glycoprotein conformation
Author(s) nameHenderson R, Edwards RJ et al.
Journal Nat Struct Mol Biol
Impact factor
9.8
Citation count: 43
Reporting molecular interaction details of hydroxychloroquine (HCQ) with the RBD of SARS-CoV-2 S Protein. 32696720
(J Biomol Struct Dyn)
PMID
32696720
Date of Publishing: 2020 Jul 22
Title Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19
Author(s) name Sehailia M, Chemat S.
Journal J Biomol Struct Dyn
Impact factor
3.22
Citation count: 6
Date of Entry 2021 Aug 2
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab 32585135
(Cell Host Microbe)
PMID
32585135
Date of Publishing: 2020 Sep 9
Title Neutralization of SARS-CoV-2 by destruction of the Prefusion Spike
Author(s) nameHuo J, Zhao Y et al.
Journal Cell Host Microbe
Impact factor
10.45
Citation count: 39
Structural characterisation of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1) 32585135
(Cell Host Microbe)
PMID
32585135
Date of Publishing: 2020 Sep 9
Title Neutralization of SARS-CoV-2 by destruction of the Prefusion Spike
Author(s) nameHuo J, Zhao Y et al.
Journal Cell Host Microbe
Impact factor
10.45
Citation count: 39
SARS-CoV-2 is neutralized by the binding of CR3022. CR3022 epitope on binding results in fusion-incompetent post-fusion state of the S-protein. 32585135
(Cell Host Microbe)
PMID
32585135
Date of Publishing: 2020 Sep 9
Title Neutralization of SARS-CoV-2 by destruction of the Prefusion Spike
Author(s) nameHuo J, Zhao Y et al.
Journal Cell Host Microbe
Impact factor
10.45
Citation count: 39
Molecular interaction studies of RBD from SARS-CoV-2 and SARS-CoV with different ACE2 orthologues 32410735
(Biochem Biophys Res Commun)
PMID
32410735
Date of Publishing: 2020 Jun 30
Title Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS -Cov , hot-spot analysis and effect of the receptor polymorphism
Author(s) nameOthman H, Bouslama Z et al.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 27
Date of Entry 2021 Jul 28
Homology based docking of SARS-CoV-2 RBD with hACE2 32410735
(Biochem Biophys Res Commun)
PMID
32410735
Date of Publishing: 2020 Jun 30
Title Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS -Cov , hot-spot analysis and effect of the receptor polymorphism
Author(s) nameOthman H, Bouslama Z et al.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 27
Date of Entry 2021 Jul 28
Molecular interaction studies of RBD from SARS-CoV-2 and SARS-CoV with different ACE2 orthologues 32410735
(Biochem Biophys Res Commun)
PMID
32410735
Date of Publishing: 2020 Jun 30
Title Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS -Cov , hot-spot analysis and effect of the receptor polymorphism
Author(s) nameOthman H, Bouslama Z et al.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 27
Date of Entry 2021 Jul 28
Molecular interaction studies of SARS-CoV-2 RBD with different variants of hACE2. 32410735
(Biochem Biophys Res Commun)
PMID
32410735
Date of Publishing: 2020 Jun 30
Title Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS -Cov , hot-spot analysis and effect of the receptor polymorphism
Author(s) nameOthman H, Bouslama Z et al.
Journal Biochem Biophys Res Commun
Impact factor
2.73
Citation count: 27
Date of Entry 2021 Aug 2
Molecular interactions between the docked Spike glycoprotein of SARSCoV2 with modeled transmembrane ACE2 receptor of pangolin (Manis javanica) 32383269
(J Med Virol)
PMID
32383269
Date of Publishing: 2020 Oct
Title In silico studies on the comparative characterization of the interactions of SARSCoV2 spike glycoprotein with ACE2 receptor homologs and human TLRs
Author(s) name Choudhury A, Mukherjee S.
Journal J Med Virol
Impact factor
2.07
Citation count: 32
Molecular interaction between the docked Spike glycoprotein of SARSCoV2 with modeled cell surface TLR6 of human. 32383269
(J Med Virol)
PMID
32383269
Date of Publishing: 2020 Oct
Title In silico studies on the comparative characterization of the interactions of SARSCoV2 spike glycoprotein with ACE2 receptor homologs and human TLRs
Author(s) name Choudhury A, Mukherjee S.
Journal J Med Virol
Impact factor
2.07
Citation count: 32
Molecular interactions between the docked Spike glycoprotein of SARSCoV2 with modeled cell surface TLR4 of human 32383269
(J Med Virol)
PMID
32383269
Date of Publishing: 2020 Oct
Title In silico studies on the comparative characterization of the interactions of SARSCoV2 spike glycoprotein with ACE2 receptor homologs and human TLRs
Author(s) name Choudhury A, Mukherjee S.
Journal J Med Virol
Impact factor
2.07
Citation count: 32
Molecular interactions between the docked Spike glycoprotein of SARSCoV2 with modeled cell surface TLR1 of human . 32383269
(J Med Virol)
PMID
32383269
Date of Publishing: 2020 Oct
Title In silico studies on the comparative characterization of the interactions of SARSCoV2 spike glycoprotein with ACE2 receptor homologs and human TLRs
Author(s) name Choudhury A, Mukherjee S.
Journal J Med Virol
Impact factor
2.07
Citation count: 32

Pathophysiology : Spike

Total row(s): 12
Select item(s)
Key Findings
Original Article
(hover to see details)
An acute lung injury model by intratracheally instilling the S1 subunit of SARS-CoV-2 Spike S protein (400 g/kg, 2 ml/kg body weight) in K18-hACE2 transgenic mice that overexpress the human receptor for SARS-CoV-2 Spike protein S, ACE2, and investigated outcomes 72 hours later. Direct author entry
(pre-publication)
Title Single intratracheal exposure to SARS-CoV-2 S1 spike protein induces acute lung injury in K18-hACE2 transgenic mice
Author(s) namePavel Solopov, Ruben Colunga Biancatelli et al.
Affiliations Pavel Solopov (Old Dominion University)| Ruben Colunga Biancatelli (Old Dominion University)| Elizabeth Sharlow (University of Virginia)| John Lazo (University of Virginia)| John Catravas (Old Dominion University, Old Dominion University)
Date of Entry 2021 Jun 15
The in vitro mutation analysis showed that the D614G mutation changes the spike protein sorting, enhances the trafficking of spike protein to the lysosome. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
To understand the mechanism of lysosomal trafficking of the spike protein, the Htet1/SD614G cells were incubated with doxycycline. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
To understand the molecular mechanism of lysosomal trafficking of the spike protein, the Htet1/SD614G cells were incubated with doxycycline and dynasore. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
To understand the molecular mechanism of lysosomal trafficking of the spike protein, the Htet1/SD614G cells were incubated with doxycycline and pitstop2. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
To understand the molecular mechanism of lysosomal trafficking of the spike protein, the Htet1/SD614G cells were incubated with nocodazole. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
To understand the molecular mechanism of lysosomal trafficking of the spike protein, the Htet1/SD614G cells were incubated with bafilomycin A1. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
The in vitro mutation analysis of the D614G mutation showed no effect on viral replication and viral infectivity in Vero E6 cells. 33106671
(Nature)
PMID
33106671
Date of Publishing: 2020 Oct 26
Title Spike mutation D614G alters SARS-CoV-2 fitness
Author(s) namePlante JA, Liu Y et al.
Journal Nature
Impact factor
24.36
Citation count: 38
Compared with the wild D614 virus, the mutant G614 virus showed increased viral replication and viral infectivity in the cell line Calu-3. 33106671
(Nature)
PMID
33106671
Date of Publishing: 2020 Oct 26
Title Spike mutation D614G alters SARS-CoV-2 fitness
Author(s) namePlante JA, Liu Y et al.
Journal Nature
Impact factor
24.36
Citation count: 38
Compared with the wild D614 virus, the mutant G614 virus showed increased viral replication and viral infectivity in the primary human airway tissue culture model. 33106671
(Nature)
PMID
33106671
Date of Publishing: 2020 Oct 26
Title Spike mutation D614G alters SARS-CoV-2 fitness
Author(s) namePlante JA, Liu Y et al.
Journal Nature
Impact factor
24.36
Citation count: 38
Hamsters infected with mutant SARS-CoV-2 (G614 virus) showed higher viral load in the nasal washes and the tracheae, but not in the lungs, than those of Hamsters infected with WT SARS-CoV-2 (D614 virus). 33106671
(Nature)
PMID
33106671
Date of Publishing: 2020 Oct 26
Title Spike mutation D614G alters SARS-CoV-2 fitness
Author(s) namePlante JA, Liu Y et al.
Journal Nature
Impact factor
24.36
Citation count: 38
The in vitro analysis of the deletion variants revealed that Var1 (deletion of QTQTN in spike protein) reduced the viral replication during late-phase, and Var2 (deletion of NSPRRAR in spike protein) didnt affect viral replication in Vero and Vero-E6 cells. 32571797
(J Virol)
PMID
32571797
Date of Publishing: 2020 Aug 17
Title Identification of Common Deletions in the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2
Author(s) nameLiu Z, Zheng H et al.
Journal J Virol
Impact factor
4.16
Citation count: 12

Epidemiology : Spike

Total row(s): 2
Select item(s)
Key Findings
Original Article
(hover to see details)
Out of 30 COVID-19 patients, 23 showed the presence of anti-N antibodies, 20 showed anti-S** antibodies, and 13 had anti-M antibodies. 33330866
(bioRxiv)
PMID
33330866
Date of Publishing: 2020 Dec 9
Title The D614G Mutation Enhances the Lysosomal Trafficking of SARS-CoV-2 Spike
Author(s) nameGuo C, Tsai SJ et al.
Journal bioRxiv
Impact factor
Its not a journal
Citation count: 1
SARS-CoV-2 transmission was associated with the role of D614G spike protein variant as 614G had a selective advantage when compared to 614D and it relates to higher viral load and infection of younger individuals but not higher mortality or clinical severity. 33275900
(Cell)
PMID
33275900
Date of Publishing: 2020 Nov 19
Title Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Author(s) nameVolz E, Hill V et al.
Journal Cell
Impact factor
27.35
Citation count: 21

Immunology : Spike

Total row(s): 91
Select item(s)
Key Findings
Original Article
(hover to see details)
In-vitro neutralization assays revealed that Israeli strain containing the P681H mutation was not associated with higher infection rates and got neutralized by sera from vaccinated individuals. Pre-print (medRXiv)
Date of Publishing 2021 Mar 25
Title A unique SARS-CoV-2 spike protein P681H strain detected in Israel
Author(s) nameNeta S. Zuckerman, Shay Fleishon et al.
Date of Entry 2021 Jun 14
In patients who had recovered from mild COVID-19 infection, the serum anti-SARS-CoV-2 Spike antibodies declined quickly within the first 4 months and then more slowly in the following 7 months. In addition, a long-lived S-specific Bone marrow plasma cells (BMPC) response was detected in COVID-19 convalescent individuals. 34030176
(Nature)
PMID
34030176
Date of Publishing: 2021 May 24
Title SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Author(s) nameTurner JS, Kim W et al.
Journal Nature
Impact factor
24.36
Citation count: 6
Deletions at positions 144/145 and 243-244 in the NTD region of S glycoprotein disrupt the binding of antibody 4A8, which defines an immunodominant epitope within the NTD. 33536258
(Science)
PMID
33536258
Date of Publishing: 2021 Feb 3
Title Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
Author(s) nameMcCarthy KR, Rennick LJ et al.
Journal Science
Impact factor
20.57
Citation count: 6
Mice immunized with adjuvanted NVX-CoV2373 vaccine had significantly higher anti-S IgG antibody titers. The antibodies showed good neutralizing activity and blocked the binding of the virus to the hACE-2 receptor. 33446655
(Nat Commun)
PMID
33446655
Date of Publishing: 2021 Jan 14
Title SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Author(s) nameTian JH, Patel N et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 5
Olive baboons immunized with adjuvanted NVX-CoV2373 vaccine had significantly higher anti-S IgG antibody titers. The antibodies showed good neutralizing activity and blocked the binding of the virus to the hACE-2 receptor. 33446655
(Nat Commun)
PMID
33446655
Date of Publishing: 2021 Jan 14
Title SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Author(s) nameTian JH, Patel N et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 5
The SARS-CoV-2 immune memory kinetics was assessed more than 6 months after infection. Spike protein-specific memory B cells were higher in number at 6 months than one month after infection. The CD4+ and CD8+ T cells decreased with a half-life of 3-5 months. 33408181
(Science)
PMID
33408181
Date of Publishing: 2021 Jan 6
Title Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Author(s) nameDan JM, Mateus J et al.
Journal Science
Impact factor
20.57
Citation count: 9
Date of Entry 2021 Jul 24
Using an evolutionary protein design algorithm, EvoDesign, thousands of stable S protein variants which keep the surface conformation and B cell epitopes intact were studied. The T cell epitope content and similarity score were then calculated. The newly designed S protein introduced 9 new MHC-II T cell epitopes that do not exist in the wildtype SARS-CoV-2. 33398234
(Comput Struct Biotechnol J)
PMID
33398234
Date of Publishing: 2020 Dec 31
Title Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering
Author(s) nameOng E, Huang X et al.
Journal Comput Struct Biotechnol J
Impact factor
5.11
Citation count: 1
Patients who had recovered showed increased anti-S IgG/IgM and high positive rates when compared to in-patients. 33310028
(Int J Infect Dis)
PMID
33310028
Date of Publishing: 2020 Dec 10
Title Dynamic Anti-Spike Protein Antibody Profiles in COVID-19 Patients
Author(s) nameBao Y, Ling Y et al.
Journal Int J Infect Dis
Impact factor
3.42
Citation count: 1
During the early stages of COVID-19, total T lymphocyte count and CD4+ T cells decrease in count. 33310028
(Int J Infect Dis)
PMID
33310028
Date of Publishing: 2020 Dec 10
Title Dynamic Anti-Spike Protein Antibody Profiles in COVID-19 Patients
Author(s) nameBao Y, Ling Y et al.
Journal Int J Infect Dis
Impact factor
3.42
Citation count: 1
CD8 T cell epitopes of 80 different human HLAs were generated for SARS-CoV-2 Spike protein. 33301503
(PLoS One)
PMID
33301503
Date of Publishing: 2020
Title CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention
Author(s) name Guo E, Guo H.
Journal PLoS One
Impact factor
2.87
Citation count: 1
34 cytotoxic T cell epitopes located in spike glycoprotein, envelope protein, membrane protein, and nucleocapsid phosphoprotein were identified. 33257716
(Sci Rep)
PMID
33257716
Date of Publishing: 2020 Nov 30
Title Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2
Author(s) nameBehmard E, Soleymani B et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
14 helper T cell epitopes located in spike glycoprotein, envelope protein, and nucleocapsid phosphoprotein were identified. 33257716
(Sci Rep)
PMID
33257716
Date of Publishing: 2020 Nov 30
Title Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2
Author(s) nameBehmard E, Soleymani B et al.
Journal Sci Rep
Impact factor
4.12
Citation count: 1
The neutralizing potential efficiency of anti-Spike-S1 IgYs (chicken egg yolk antibodies) that blocks the binding of various variants of SARS-CoV-2 spike protein to ACE-2 receptor was researched. 33191178
(Int Immunopharmacol)
PMID
33191178
Date of Publishing: 2020 Nov 3
Title Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2
Author(s) nameWei S, Duan S et al.
Journal Int Immunopharmacol
Impact factor
3.38
Citation count: 1
Sera from hamsters infected with the WT SARS-CoV-2 (D614) virus showed higher neutralization against the G614 virus than against the D614 virus. 33106671
(Nature)
PMID
33106671
Date of Publishing: 2020 Oct 26
Title Spike mutation D614G alters SARS-CoV-2 fitness
Author(s) namePlante JA, Liu Y et al.
Journal Nature
Impact factor
24.36
Citation count: 38
A monoclonal Antibody (2B04) potently inhibited SARS-CoV-2 infection with an IC50 of 3.007 ng/mL. 33035201
(JCI Insight)
PMID
33035201
Date of Publishing: 2020 Nov 19
Title Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors.
Author(s) nameZeng C, Evans JP et al.
Journal JCI Insight
Impact factor
6.014
Citation count: 4
Studying the kinetics and antibody isotype profile to the RBD of S protein in individuals with severe infection was done along with cross-reactivity of the responses with different coronaviruses RBDs. Characterization of assay performance using the dried blood spots was done which can provide an alternative to serum or plasma. 33033172
(Sci Immunol)
PMID
33033172
Date of Publishing: 2020 Oct 8
Title Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
Author(s) nameIyer AS, Jones FK et al.
Journal Sci Immunol
Impact factor
8.16
Citation count: 26
Monoclonal antibody MD63 did not show neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Monoclonal antibody MD65 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Monoclonal antibody MD17 showed a poor neutralizing activity (NT50) in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Monoclonal antibody MD62 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Monoclonal antibody MD45 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Monoclonal antibody MD67 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Monoclonal antibody MD29 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. 32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 7
Peripheral blood mononuclear cells (PBMCs)from unexposed donors was used to identify CD4+ cells recognising the SARS-CoV-2 epitope. A total of 142 SARS-CoV-2 epitopes were identified-66 from spike protein and 76 from the remainder of the genome. 32753554
(Science)
PMID
32753554
Date of Publishing: 2020 Oct 2
Title Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Author(s) nameMateus J, Grifoni A et al.
Journal Science
Impact factor
20.57
Citation count: 86
Date of Entry 2021 Sep 5
Four linear B-cell epitopes on the S and N viral proteins were identified. 32711254
(EBioMedicine)
PMID
32711254
Date of Publishing: 2020 Aug
Title Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity
Author(s) nameAmrun SN, Lee CY et al.
Journal EBioMedicine
Impact factor
6.49
Citation count: 9